349 related articles for article (PubMed ID: 22093196)
1. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Price DL; Chen R; Udell J; Raz I
Am Heart J; 2011 Nov; 162(5):818-825.e6. PubMed ID: 22093196
[TBL] [Abstract][Full Text] [Related]
2. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Frederich R; Alexander JH; Fiedorek FT; Donovan M; Berglind N; Harris S; Chen R; Wolf R; Mahaffey KW
Postgrad Med; 2010 May; 122(3):16-27. PubMed ID: 20463410
[TBL] [Abstract][Full Text] [Related]
3. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
Jain R
Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
[TBL] [Abstract][Full Text] [Related]
4. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Leiter LA; Teoh H; Braunwald E; Mosenzon O; Cahn A; Kumar KM; Smahelova A; Hirshberg B; Stahre C; Frederich R; Bonnici F; Scirica BM; Bhatt DL; Raz I;
Diabetes Care; 2015 Jun; 38(6):1145-53. PubMed ID: 25758769
[TBL] [Abstract][Full Text] [Related]
6. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
[TBL] [Abstract][Full Text] [Related]
7. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
8. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Udell JA; Bhatt DL; Braunwald E; Cavender MA; Mosenzon O; Steg PG; Davidson JA; Nicolau JC; Corbalan R; Hirshberg B; Frederich R; Im K; Umez-Eronini AA; He P; McGuire DK; Leiter LA; Raz I; Scirica BM;
Diabetes Care; 2015 Apr; 38(4):696-705. PubMed ID: 25552421
[TBL] [Abstract][Full Text] [Related]
9. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Scirica BM; Braunwald E; Raz I; Cavender MA; Morrow DA; Jarolim P; Udell JA; Mosenzon O; Im K; Umez-Eronini AA; Pollack PS; Hirshberg B; Frederich R; Lewis BS; McGuire DK; Davidson J; Steg PG; Bhatt DL;
Circulation; 2014 Oct; 130(18):1579-88. PubMed ID: 25189213
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).
Gutierrez JA; Scirica BM; Bonaca MP; Steg PG; Mosenzon O; Hirshberg B; Im K; Raz I; Braunwald E; Bhatt DL
Am J Cardiol; 2019 Jan; 123(1):145-152. PubMed ID: 30366601
[TBL] [Abstract][Full Text] [Related]
12. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
Leiter LA; Teoh H; Mosenzon O; Cahn A; Hirshberg B; Stahre CA; Hoekstra JB; Alvarsson M; Im K; Scirica BM; Bhatt DL; Raz I;
Diabetes Obes Metab; 2016 Feb; 18(2):186-90. PubMed ID: 26443993
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
[TBL] [Abstract][Full Text] [Related]
14. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Rosenstock J; Sankoh S; List JF
Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
Cobble ME; Frederich R
Cardiovasc Diabetol; 2012 Jan; 11():6. PubMed ID: 22248301
[TBL] [Abstract][Full Text] [Related]
17. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Mosenzon O; Leibowitz G; Bhatt DL; Cahn A; Hirshberg B; Wei C; Im K; Rozenberg A; Yanuv I; Stahre C; Ray KK; Iqbal N; Braunwald E; Scirica BM; Raz I
Diabetes Care; 2017 Jan; 40(1):69-76. PubMed ID: 27797925
[TBL] [Abstract][Full Text] [Related]
18. [SAVOR TIMI 53 - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus].
Spinar J; Smahelová A
Vnitr Lek; 2013 Nov; 59(11):1003-7. PubMed ID: 24279445
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Cook W; Bryzinski B; Slater J; Frederich R; Allen E
Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
Hardy G
Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
[No Abstract] [Full Text] [Related]
[Next] [New Search]